Financing of Young Biotechnology Companies (SECA (Swiss Private Equity and Corporate Finance Association))

Summary

• The study by Oliver Thalmann examines the challenges and financing options for young biotechnology companies across 305 pages.p.1
• The empirical part includes statistical analyses of 14391 corporate licensing deals worldwide between biotech and pharmaceutical companies.p.1
• The work features 26 illustrations and 33 tables detailing financing structures and market interdependencies.p.1
• The book is published as Volume 5 of the Swiss Private Equity and Corporate Finance Association series, priced at EUR 38.50 or CHF 58.p.1

Key insights

1. Securing sustainable financing is the central challenge in the development of young biotechnology startups due to long development cycles and high risk.p.1
2. The study analyzes strategic options for biotech startups within their industry-specific context.p.1
3. Empirical evidence is based on a survey of CEOs, CFOs, investors, and advisors, alongside extensive statistical data.p.1
4. Financing structures in licensing agreements directly influence the ultimate success of biotech-pharma collaborations.p.1
5. There are strong interdependencies between the capital market and the licensing deal market in the biotechnology sector.p.1
6. Licensing deals generate key signal effects that provide valuable guidance for financial investors and pharmaceutical corporations.p.1